Management of hidradenitis suppurativa in pregnancy

J Am Acad Dermatol. 2017 May;76(5):979-989. doi: 10.1016/j.jaad.2016.10.032. Epub 2016 Dec 29.

Abstract

Hidradenitis suppurativa is a debilitating inflammatory skin disease with a chronic course and often disappointing response to treatment. Though a minority of persons (20%) reports symptom remission during pregnancy, the vast majority experiences no relief (72%), and few experience clinical deterioration (8%). Disease flares are also observed post-partum. The pathophysiological basis for pregnancy-associated fluctuations in clinical status is currently unknown. Because most women with HS require ongoing management throughout pregnancy, it is important to evaluate the suitability and safety of current treatment options for pregnant women. The following review will outline current management strategies for HS and their compatibility with pregnancy and lactation.

Keywords: hidradenitis suppurativa; inflammation; inflammatory skin disease; lactation; post-partum; pregnancy.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Biological Products / adverse effects
  • Contraindications
  • Cryotherapy
  • Female
  • Hidradenitis Suppurativa / drug therapy
  • Hidradenitis Suppurativa / surgery
  • Hidradenitis Suppurativa / therapy*
  • Homeopathy
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Lactation
  • Laser Therapy
  • Metformin / therapeutic use
  • Pain Management
  • Pregnancy
  • Pregnancy Complications / drug therapy
  • Pregnancy Complications / surgery
  • Pregnancy Complications / therapy*
  • Smoking Cessation

Substances

  • Anti-Bacterial Agents
  • Biological Products
  • Immunosuppressive Agents
  • Metformin